Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.0 AMA PRA Category 1 CreditsTMPhysicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech and Astellas, Lilly USA, LLC and Novartis Pharmaceuticals Corporation.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

14th Annual International Lung Cancer Congress®

14th Annual International Lung Cancer Congress®


Agenda


Thursday, July 25, 2013  
6:00am Registration and Breakfast  
7:00am Welcome and Introductions  
7:05am Pre-Session Survey  
State of the Art: Early-Stage Non-small Cell Lung Cancer (NSCLC) David R. Gandara, MD
7:15am Optimal Application of Adjuvant Therapy in NSCLC Silvia Novello, MD, PhD
7:35am Question-and-Answer Session  
Optimizing NSCLC Staging: EBUS vs. Mediastinoscopy Roy S. Herbst, MD, PhD
7:40am Endobronchial Ultrasound Ken Y. Yoneda, MD
7:55am Mediastinoscopy Stephen G. Swisher, MD, FACS
8:10am Question-and-Answer Session  
Surgical Resection vs. SBRT in Patients with NSCLC and Poor Pulmonary Ken Y. Yoneda, MD
8:15am Surgical Resection Dominique Grunewald, MD, PhD
8:30am Stereotactic Body Radiotherapy Hak Choy, MD
8:45am Question-and-Answer Session  
8:50am Role of the Pulmonologists in Diagnosis and Treatment Selection for Lung Cancer Paul Baas, MD, PhD
9:10am Question-and-Answer Session  
9:15am Cased-Based Panel Discussion: Staging and Management of Early Stage NSCLC Chair: Hak Choy, MD,
Panel: Paul Baas, MD, PhD; David P. Carbone, MD, PhD; Dominique Grunenwald, MD, PhD; Silvia Novello, MD, PhD; Stephen G. Swisher, MD, FACS; Ken Y. Yoneda, MD
9:35am Break  
State of the Art in Combined Modality Therapy for NSCLC Walter J. Curran, Jr, MD
10:00am State of the Art: Multimodality Therapy Everett E. Vokes, MD
10:20am Question-and-Answer Session  
10:25am Surgical Approaches to Locally Advanced NSCLC Hisao Asamura, MD
10:45am Question-and-Answer Session  
10:50am Optimizing the Dose and Schedule of Radiation Therapy in Stage III NSCLC Walter J. Curran, Jr, MD
11:10am Question-and-Answer Session  
11:15am Integration and Targeted Agents Into Combined Modality Therapy for NSCLC Corey J. Langer, MD, FACP
11:35am Question-and-Answer Session  
11:40am Post-Session Survey  
11:50am Case-Based Panel Discussion: Combined Modality Therapy Chair: Everett E. Vokes, MD
Panel: Hisao Asamura, MD; Hak Choy, MD; Walter J. Curran, Jr, MD; Corey Langer, MD, FACP; Keunchil Park, MD, PhD; Giorgio V. Scagliotti, MD, PhD
12:10pm Poster Discussant 1:
  • Differential Expression of Regulatory T Cells and Th17 cells Are Indicative of Tumor Recurrence in pN0 Stage I Lung Cancer Patients
  • First-line vs Second-line Chemotherapy with Pemetrexed in Advanced Pulmonary Adenocarcinoma
  • Maintenance Therapy with Pemetrexed after Induction Therapy with Pemetrexed plus Cisplatin for Advanced Pulmonary adenocarcinoma
  • 1,2,3,4,6-penta-O-galloyl-β-D-glucopyranose Sensitizes Resistant A459–CR Lung Cancer Cells to Cisplatin
Keunchil Park, MD, PhD
12:30pm Break for Lunch (Lunch on Own)  
Workshop 1: Multidisciplinary Tumor Board Chair: Karen Kelly, MD
2:00pm 1. Surgical Case
2. Radiation Therapy Case
3. Pulmonary Diagnosis and Intervention Case
4. Advanced Stage NSCLC Case
Tumor Board:
Hisao Asamura, MD; Paul Baas, MD, PhD; Laurie Gaspar, MD; Giorgio Scagliotti, MD, PhD; Ken Y. Yoneda, MD
4:00pm Adjourn for the Day  
6:00pm - 7:00pm Welcome Reception in the Exhibit Hall  

Friday, July 26, 2013
 
6:00am Registration and Breakfast  
7:00am Welcome and Introductions  
7:05am Pre-Session Survey  
State of the Art Treatment of Advanced Lung Cancer Primo Lara, Jr, MD
7:15am Keynote: State of the Art: Lung Cancer Paul Bunn, Jr, MD
7:35am Question-and-Answer Session  
7:40am Antiangiogenic Agents Heather A. Wakelee, MD
8:00am Question-and-Answer Session  
8:05am ALK Inhibitors Tianhong Li, MD, PhD
8:25am Question-and-Answer Session  
8:30am c-Met Inhibitors Alex A. Adjei, MD, PhD, FACP
8:50am Question-and-Answer Session  
8:55am Immunotherapy in Lung Cancer David P. Carbone, MD, PhD
9:15am Question-and-Answer Session  
9:20am Incorporating Next-Generation Sequencing for Molecular Profiling: Future Implications for Treatment Philip C. Mack, PhD
9:40am Question-and-Answer Session  
9:45am Case-Based Panel Discussion: Advanced-Stage NSCLC Chair: Primo Lara, Jr, MD
Panel: Alex A. Adjei, MD, PhD, FACP; Paul Bunn, Jr, MD; David P. Carbone, MD, PhD; Karen Kelly, MD; Tianhong Li, MD, PhD; Philip C. Mack, PhD; Heather A. Wakelee, MD
10:05am Break  
Sixth Annual Addario Foundation Keynote Lecture David R. Gandara, MD and Roy S. Herbst, MD, PhD
10:30am Lung Cancer: A Global War That Demands a Global Effort Tony S.K. Mok, BMSc, MD, FRCPC
Personalized Medicine for Mesothelioma and SCLC Roy S. Herbst, MD, PhD
11:00am Mesothelioma Harvey I. Pass, MD
11:20am Question-and-Answer Session  
11:25am Current Approaches for LD-SCLC Laurie Gaspar, MD
11:45am Question-and-Answer Session  
11:50am How I Treat: ED-SCLC Primo Lara, Jr, MD
12:10am Question-and-Answer Session  
12:15pm Post-Session Survey  
12:25pm Panel Discussion: Personalized Medicine for Mesothelioma and SCLC Chair: Primo Lara, Jr, MD
Panel: Paul Baas, MD, PhD; Paul Bunn, Jr, MD; Laurie Gaspar, MD; Harvey I. Pass, MD; Rolf A. Stahel, MD
12:45pm Poster Discussant 2
  • The Safety and Efficacy of Robotic Lobectomy in Patients ≥75 years old Compared with Traditional Open Lobectomy
  • Is Robotic Lobectomy Cost Effective? A Single-Institution Review of Perioperative and Financial Outcomes
Hiaso Asamura, MD
1:05pm Break for Lunch (Lunch on Own)  
Workshop 2: The Next Generation of Agents for Lung Cancer  
2:20pm New Targets for Lung Cancer: Lessons Learned from the TCGA and Synthetic Lethal Screens David P. Carbone, MD, PhD
2:30pm Question-and-Answer Session  
2:35pm Targeting the PI3K/AKT Axis: Picking a Winner Vassiliki Papadimitrakopoulou, MD
2:45pm Question-and-Answer Session  
2:50pm Approaches to Inhibiting bFGFR - Are They Ready for Primetime? Paul Bunn, Jr, MD
3:00pm Question-and-Answer Session  
3:05pm PARP Inhibitors in Lung Cancer, Molecular Predictors and Combination Therapy Primo Lara, Jr, MD
3:15pm Question-and-Answer Session  
3:10pm Break  
3:45pm MEK Inhibition: What Progress Have We Made? David R. Gandara, MD
3:55pm Question-and-Answer Session  
4:00pm Reversing Resistance to EGFR TKIs - Approaches in the Front-Line and Refractory Setting Fred R. Hirsch, MD, PhD
4:10pm Question-and-Answer Session  
4:15pm Targeting KRAS in Lung Cancer: Search for the Holy Grail Roy S. Herbst, MD, PhD
4:25pm Question-and-Answer Session  
4:30pm Adjourn for the Day  
6:00pm - 7:00pm Get Acquainted Reception in the Exhibit Hall  

Saturday, July 27, 2013
 
6:00am Registration and Breakfast  
7:00am Welcome and Introductions  
7:05am Pre-Session Survey  
Maintenance and Second-line Therapy in Advanced NSCLC Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC
  Debate: Maintenance Therapy is Standard of Care for Lung Cancer Moderator:
Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC
7:15am Pro Karen Kelly, MD
7:30am Con Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC
7:45am Question-and-Answer Session  
7:50am Approaches to Therapy of Metastatic NSCLC: Second-line and Beyond Roy S. Herbst, MD, PhD
8:10am Question-and-Answer Session  
8:15am Post-Session Survey  
8:25am Case-Based Panel Discussion: Maintenance Therapy and Beyond Chair: Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC
Panel: Paul Bunn, Jr, MD; Roy S. Herbst, MD, PhD; Karen Kelly, MD; Corey J. Langer, MD, FACP; Silvia Novello, MD, PhD
8:45am Break  
Cooperative Group Update: "A Rose By Any Other Name?" Roy S. Herbst, MD, PhD
9:10am SPORE Update Jill M. Siegfried, PhD
9:30am Europe Rolf A. Stahel, MD
9:50am Asia Keunchil Park, MD, PhD
10:10am Alliance Everett E. Vokes, MD
10:30am SWOG David R. Gandara, MD
10:50am NRG Oncology Corey J. Langer, MD, FACP
11:10am NCI-Canada Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC
11:30am ECOG-ACRIN Corey J. Langer, MD, FACP
11:50am CME-Certified Satellite Symposium:
In General Session Room (Lunch Provided)
Heat Shock Protein 90 as a Therapeutic Target in Lung Cancer: Rationale and Current Progress
Activity Chairperson: Roy S. Herbst, MD, PhD
Faculty: David R. Gandara, MD; Laurie Gaspar, MD
Personalized Medicine for NSCLC David R. Gandara, MD
1:05pm Pre-Session Survey  
1:15pm Keynote: Individualized Therapy in Lung Cancer: Where are We in 2013? Giorgio V. Scagliotti, MD, PhD
1:35pm Question-and-Answer Session  
1:40pm Biomarkers for Personalized Lung Cancer Therapy Fred R. Hirsch, MD, PhD
2:00pm Question-and-Answer Session  
2:05pm The Role of Molecular Diagnostics Tetsuya Mitsudomi, MD, PhD
2:25pm Question-and-Answer Session  
2:30pm Break  
2:55pm Master Protocol Designs for Implementing Personalized Medicine Roy S. Herbst, MD, PhD
3:15pm Question-and-Answer Session  
3:20pm Optimizing Care for Special Populations in Lung Cancer (Women, Elderly, PS2) Rogerio C. Lilenbaum, MD
3:40pm Question-and-Answer Session  
3:45pm Post-Session Survey  
3:55pm Case-Based Panel Discussion: Personalized Medicine Chair: David R. Gandara, MD
Panel: Alex A. Adjei, MD, PhD, FACP; David P. Carbone, MD, PhD; Roy S. Herbst, MD, PhD; Fred R. Hirsch, MD, PhD; Rogerio C. Lilenbaum, MD; Tetsuya Mitsudomi, MD, PhD; Tony S.K. Mok, BMSc, MD, FRCPC; Giorgio V. Scagliotti, MD, PhD;
Rolf A. Stahel, MD
4:15pm Congress Adjournment  







Become a Member

Forgot Password?
Filter By